Literature DB >> 15701783

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.

Joseph Menzin1, Luke Boulanger, Ole Hauch, Mark Friedman, Cheryl Beadle Marple, Gail Wygant, Judith S Hurley, Stephen Pezzella, Scott Kaatz.   

Abstract

BACKGROUND: Warfarin is recommended for prevention of stroke in patients with atrial fibrillation who are at moderate or high risk, but requires intensive management to achieve safe and optimal anticoagulation control. Anticoagulation clinics are often used to administer warfarin therapy more effectively.
OBJECTIVE: To collect data from multiple sites and assess the quality and costs associated with anticoagulation clinic services.
METHODS: A random sample of 600 adults with chronic nonvalvular atrial fibrillation (CNVAF) receiving warfarin was selected from anticoagulation clinics affiliated with 3 health plans. Patients were identified between 1996 and 1998 and followed for up to one year. We assessed the proportion of time that international normalized ratio (INR) values were within the recommended range (2.0-3.0) and the costs of anticoagulation clinic care.
RESULTS: Patients had an average of 18 clinic contacts over a mean duration of follow-up of 10.5 months. On average, patients were within the recommended INR range 62% of this time, with 25% of days below range and 13% above range. The mean per-patient cost of warfarin monitoring over the follow-up period averaged $261 at site A, $305 at site B, and $205 at site C (in 2003 US$). Mean costs for patients treated for one full year were $288, $339, and $216, respectively.
CONCLUSIONS: In 3 geographically diverse health plans, anticoagulation clinics provided a generally higher quality of control than previously reported in other observational studies. This study highlights the costs of obtaining this level of control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701783     DOI: 10.1345/aph.1E169

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  14 in total

Review 1.  Managing oral anticoagulation requires expert experience and clinical evidence.

Authors:  Alex C Spyropoulos
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 2.  Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance.

Authors:  Jennifer L Donovan; Julie A Drake; Peter Whittaker; Maichi T Tran
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

3.  The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.

Authors:  Patrick W Sullivan; Thomas W Arant; Samuel L Ellis; Heather Ulrich
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  The use of warfarin as thromboprophylaxis for lower limb arthroplasty.

Authors:  Mark R Dunbar; Piyush K Upadhyay; Shanmugam Karthikeyan
Journal:  Ann R Coll Surg Engl       Date:  2008-07-02       Impact factor: 1.891

5.  Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.

Authors:  Joyce H S You
Journal:  J Gen Intern Med       Date:  2013-10-17       Impact factor: 5.128

Review 6.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

7.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

8.  Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

Authors:  Joyce H S You; Kia K N Tsui; Raymond S M Wong; Gergory Cheng
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

Review 9.  Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.

Authors:  Michael Rud Lassen; Volker Laux
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.

Authors:  Taru Hallinen; Erkki J Soini; Christian Asseburg; Pekka Kuosmanen; Ari Laakkonen
Journal:  BMJ Open       Date:  2014-02-27       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.